<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00828165</url>
  </required_header>
  <id_info>
    <org_study_id>ARRAY-300-101</org_study_id>
    <nct_id>NCT00828165</nct_id>
  </id_info>
  <brief_title>A Safety Study of ARRY-300 in Healthy Subjects</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Array BioPharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Array BioPharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1 study, involving a 1-day dosing period (up to 3 dosing periods per
      subject), designed to test the safety of investigational study drug ARRY-300 in healthy
      subjects. Approximately 12 healthy subjects from the US will be enrolled in this study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Characterize the safety profile of the study drug in terms of adverse events, clinical laboratory tests, vital signs and electrocardiograms.</measure>
    <time_frame>Duration of study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Characterize the pharmacokinetics (PK) of the study drug and metabolites in terms of plasma concentrations.</measure>
    <time_frame>Following a single dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Characterize the pharmacodynamic (PD) activity of the study drug on biomarkers.</measure>
    <time_frame>Duration of study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>ARRY-300</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARRY-300, MEK inhibitor; oral</intervention_name>
    <description>single dose, escalating</description>
    <arm_group_label>ARRY-300</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>matching placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Healthy male or female (females must be of non-childbearing potential) between the
             ages of 18 and 50 years, inclusive.

          -  Body mass index (BMI) of 18 kg/m2 to 35 kg/m2; and a total body weight &gt; 50 kg (110
             lbs) and &lt; 113 kg (280 lbs).

          -  Additional criteria exist.

        Key Exclusion Criteria:

          -  Evidence or history of clinically significant hematologic, renal, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic,
             dermatologic, or allergic disease (including drug allergies that are clinically
             significant and not remote, but excluding untreated, asymptomatic, seasonal allergies
             at the time of dosing).

          -  A condition possibly affecting drug absorption (e.g., gastrectomy).

          -  Women who are pregnant or breastfeeding.

          -  A positive test for drugs or alcohol.

          -  Use of tobacco- or nicotine-containing products in excess of 5 cigarettes per day, or
             daily use of pipe, cigar, chewing tobacco or nicotine gum or patches.

          -  Treatment with an investigational drug within 30 days prior to first dose of study
             drug.

          -  Use of prescription or nonprescription drugs, vitamins, grapefruit juice, and dietary
             or herbal supplements within 14 days prior to the first dose of study drug. As
             exceptions, acetaminophen may be used at doses of ≤ 1 g/day or ibuprofen may be used
             at doses of ≤ 800 mg/day until 24 hours prior to first dose of study drug.

          -  Blood donation of ≥ 1 pint within 30 days prior to first dose of study drug.

          -  Evidence of hepatitis B or C, or human immunodeficiency virus (HIV) infection upon
             serological testing.

          -  Additional criteria exist.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>PPD Development, LP</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78744</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 22, 2009</study_first_submitted>
  <study_first_submitted_qc>January 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 23, 2009</study_first_posted>
  <last_update_submitted>August 29, 2012</last_update_submitted>
  <last_update_submitted_qc>August 29, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 30, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

